Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $77.1818.

Several brokerages recently weighed in on VERA. Evercore boosted their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. The Goldman Sachs Group raised their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a research note on Friday, November 28th. Finally, Pivotal Research set a $73.00 price target on Vera Therapeutics in a report on Friday, December 5th.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $42.37 on Wednesday. The business’s fifty day moving average price is $46.77 and its two-hundred day moving average price is $35.26. The stock has a market cap of $2.97 billion, a PE ratio of -10.62 and a beta of 1.16. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. Vera Therapeutics has a one year low of $18.53 and a one year high of $56.05.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Patrick G. Enright purchased 5,882 shares of the firm’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director owned 5,882 shares in the company, valued at approximately $249,985. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC increased its position in Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Optimize Financial Inc grew its stake in shares of Vera Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the period. Virtus Investment Advisers LLC increased its holdings in shares of Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after buying an additional 290 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after buying an additional 424 shares during the period. Finally, Invesco Ltd. boosted its holdings in Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares during the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.